Trial Profile
Prospective Anti-HCV Trial of Peg-Interferon and Ribavirin in Subjects of First Nations and Caucasian Ethnicity: PRAIRIE Study.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Peginterferon (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms PRAIRE
- 15 May 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 04 Mar 2010 Roche added as trial sponsor as reported by ClinicalTrials.gov.
- 21 Aug 2009 New trial record